AtriCure Announces First Use of the AtriClip PRO-Mini® Device
AtriCure to Announce First Quarter 2025 Financial Results
AtriCure, Inc. (NASDAQ: ATRC) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $66.00 to $52.00. They now have a "buy" rating on the stock.
AtriCure, Inc. (NASDAQ: ATRC) had its "buy" rating re-affirmed by analysts at BTIG Research.
AtriCure, Inc. (NASDAQ: ATRC) had its price target lowered by analysts at JPMorgan Chase & Co. from $51.00 to $46.00. They now have an "overweight" rating on the stock.